UBS Group
IMVT icon

UBS Group’s Immunovant IMVT Stock Holding History

UBS Group’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,000
Closed -$384K – 10586
2025
Q2 		$384K Hold
24,000
– – ﹤0.01% 6234
2025
Q1 		$410K Hold
24,000
– – ﹤0.01% 6008
2024
Q4 		$594K Hold
24,000
– – ﹤0.01% 5718
2024
Q3 		$684K Hold
24,000
– – ﹤0.01% 4974
2024
Q2 		$634K Buy
+24,000
New +$683K ﹤0.01% 4808

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's IMVT Position: Q2 2026 in Review

UBS Group reduced its Immunovant (IMVT) stake by 31% in Q2 2026, selling an estimated $6.47M and leaving 472,122 shares worth $18.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2790.

UBS Group first reported a position in IMVT in Q4 2019 and has held it in 26 quarters since. The position peaked at $18.6M in Q4 2025. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • UBS Group held 472,122 shares of Immunovant worth $18.2M as of Q2 2026.
  • UBS Group sold 212,429 Immunovant shares in Q2 2026, an estimated $6.47M.
  • Immunovant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2790 holding.
  • UBS Group first reported a position in Immunovant in Q4 2019 and has held it in 26 quarters since.
  • UBS Group's Immunovant position peaked at $18.6M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.